Aratana Therapeutics Inc (NASDAQ:PETX) – Equities research analysts at William Blair increased their Q3 2018 earnings per share (EPS) estimates for Aratana Therapeutics in a research note issued on Monday, Zacks Investment Research reports. William Blair analyst J. Kreger now forecasts that the biopharmaceutical company will post earnings of ($0.08) per share for the quarter, up from their previous estimate of ($0.09). William Blair also issued estimates for Aratana Therapeutics’ Q4 2018 earnings at $0.24 EPS and FY2019 earnings at $0.42 EPS.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s revenue was up 1440.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.38) earnings per share.
Several other equities analysts also recently commented on PETX. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 18th. HC Wainwright started coverage on Aratana Therapeutics in a research report on Friday, November 17th. They issued a “buy” rating and a $10.00 target price on the stock. Jefferies Group set a $9.00 target price on Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 16th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $6.00 target price on shares of Aratana Therapeutics in a research report on Monday, December 18th. Finally, CL King started coverage on Aratana Therapeutics in a research report on Wednesday, December 27th. They issued a “neutral” rating on the stock. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Aratana Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.55.
Aratana Therapeutics (PETX) opened at $5.22 on Wednesday. The firm has a market capitalization of $224.46, a P/E ratio of -3.60 and a beta of 3.36. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. Aratana Therapeutics has a 12-month low of $4.81 and a 12-month high of $8.30.
Hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new stake in Aratana Therapeutics during the second quarter worth $12,948,000. Broadfin Capital LLC lifted its stake in Aratana Therapeutics by 40.3% during the second quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock worth $37,487,000 after purchasing an additional 1,489,500 shares during the last quarter. Franklin Resources Inc. lifted its stake in Aratana Therapeutics by 11.2% during the second quarter. Franklin Resources Inc. now owns 6,011,309 shares of the biopharmaceutical company’s stock worth $43,462,000 after purchasing an additional 604,518 shares during the last quarter. AWM Investment Company Inc. lifted its stake in Aratana Therapeutics by 49.4% during the second quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after purchasing an additional 525,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Aratana Therapeutics by 197.0% during the second quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock worth $2,754,000 after purchasing an additional 252,655 shares during the last quarter. Institutional investors and hedge funds own 73.76% of the company’s stock.
In related news, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.70, for a total value of $5,075,941.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Craig A. Tooman sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the completion of the sale, the insider now owns 75,024 shares of the company’s stock, valued at $395,376.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,087,032 shares of company stock valued at $6,344,891. 5.20% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/01/14/william-blair-analysts-increase-earnings-estimates-for-aratana-therapeutics-inc-petx-updated-updated-updated.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.